Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sotevtamab |
Synonyms | |
Therapy Description |
Sotevtamab is a monoclonal antibody that inhibits the activity of tumor associated human clusterin (sCLU), potentially decreasing epithelial-to-mesenchymal transition and reducing tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 8577)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sotevtamab | AB 16B5|AB16B5|AB-16B5 | Sotevtamab is a monoclonal antibody that inhibits the activity of tumor associated human clusterin (sCLU), potentially decreasing epithelial-to-mesenchymal transition and reducing tumor growth (J Clin Oncol 42, 2024 (suppl 16; abstr 8577)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02412462 | Phase I | Sotevtamab | Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy | Completed | CAN | 0 |